Study cohort of HLA-A*02 positive patients with chronic HBV infection
| Characteristics | HLA-A*02 positive patients (n=35)* | |||
| HBsAg groups (IU/mL) | HBcrAg groups (Log U/mL) | |||
| <100 | ≥10 000 | <3 | ≥3 | |
| Number of patients | 19 | 16 | 25 | 10 |
| HBsAg (IU/mL): median (range) | 29 (0.76–116)† | 18 303 (10 266–52 891) | 43 (0.76–27 064) | 19 870.5 (10 266–52 891) |
| HBcrAg (LogU/mL): median (range) | 2 (2–2.5) | 3.05 (2–4.3) | 2 (2–2.8) | 3.2 (3–4.3) |
| Sex (male/female) | 11/8 | 7/9 | 15/10 | 3/7 |
| Age (years): median (range) | 51 (29–67) | 35 (19–57) | 50 (29–67) | 28 (19–41) |
| ALT level (IU/L): median (range) | 19 (4–46) | 24 (13–126) | 20 (4–50) | 25 (13–126) |
| HBV DNA <2000 IU/mL (%) | 94.7 | 100 | 96 | 100 |
| HBeAg (-/+/n.d.) | 15/0/4 | 12/0/4 | 20/0/5 | 7/0/3 |
| NA therapy / no treatment / n.d. | 13/4/2 | 4/12/0 | 15/8/2 | 2/8/0 |
*One patient (HBsAg=0.76 IU/mL and HBcrAg=2 Log U/mL) is excluded from final phenotyping analysis because the frequencies of antigen-specific cells were below the limit of detection (10 dextramer positive cells).
†HBsAg level of one patient from the group of HBsAg <100 is 116 IU/mL.
ALT, alanine transaminase; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; NA, nucleos(t)ide analogue; n.d., not determined.